2009
Incidence of Non-AIDS-Defining Malignancies in HIV-Infected Versus Noninfected Patients in the HAART Era: Impact of Immunosuppression
Bedimo RJ, McGinnis KA, Dunlap M, Rodriguez-Barradas MC, Justice AC. Incidence of Non-AIDS-Defining Malignancies in HIV-Infected Versus Noninfected Patients in the HAART Era: Impact of Immunosuppression. JAIDS Journal Of Acquired Immune Deficiency Syndromes 2009, 52: 203-208. PMID: 19617846, PMCID: PMC2814969, DOI: 10.1097/qai.0b013e3181b033ab.Peer-Reviewed Original ResearchConceptsActive antiretroviral therapy (HAART) eraAntiretroviral therapy eraIncidence rate ratiosCD4 countTherapy eraAnal cancerLow CD4 countHigher CD4 countsMedian CD4 countImpact of immunosuppressionRate ratioCohort of veteransNon-AIDSNoninfected patientsHAART eraUninfected patientsHodgkin's lymphomaIncidence rateProstate cancerHIVPatientsCancerIndividual cancersMalignancyIncidence
2003
Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era
King JT, Justice AC, Roberts MS, Chang CC, Fusco JS. Long-Term HIV/AIDS Survival Estimation in the Highly Active Antiretroviral Therapy Era. Medical Decision Making 2003, 23: 9-20. PMID: 12583451, DOI: 10.1177/0272989x02239652.Peer-Reviewed Original ResearchConceptsCells/mm3Long-term survivalCD4 cell countAge-associated mortalityTreatment failureHIV/AIDSUS life tablesCell countActive antiretroviral therapy (HAART) eraBaseline CD4 cell countHIV/AIDS patientsLong-term survival dataShort-term survival dataAntiretroviral therapy eraPre-HAART cohortTreatment mortality rateActive antiretroviral therapyTreatment failure rateRisk of mortalitySurvival dataShort-term survivalHAART failureTherapy eraAntiretroviral therapyObservational cohort